GV, Alphabet Inc's venture capital arm, led a US$58.5 million investment to launch Verve Therapeutics, a new biotech focused on developing therapies that edit the human genome to treat heart diseases.
The company said it will only develop treatments that involve editing adult cells, so the effects of genetic manipulation cannot be passed on to future generations.
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más:
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Brazil cosmetics company Natura to invest US$5m in new brands through venture capital funds[SAO PAULO] Brazil cosmetics company Natura intends to invest up to US$5 million in new brands in beauty and wellness segments in Europe and the United States through venture capital funds, executives said on Friday. Read more at The Business Times.
Fuente: BusinessTimes - 🏆 15. / 51 Leer más »
More funds to help companies train workers, raise wages
Fuente: TODAYonline - 🏆 1. / 99 Leer más »
More funding for companies that work with unions to prepare workers for transformation: DPM HengSINGAPORE - Technological advancements should help workers do their jobs better, not replace them, said Deputy Prime Minister Heng Swee Keat on Wednesday (May 1).. Read more at straitstimes.com.
Fuente: The Straits Times - 🏆 8. / 63 Leer más »